TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston Scientific (BSX – Research Report) with bullish ...

Over the last 7 days, the United States market has risen 1.0% and is up 28% over the last 12 months, with earnings forecasted ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

As of the latest trading close, TGTX, a Healthcare sector stock, is trading -3.15% below its 52-week high but remains 285.29% above its 52-week low. The Average True Range (ATR) (14 days) of 1.42 ...

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...